Persista Bio Secures Two NIH Grants to Advance O2Line™ Oxygenated Cell Therapy Platform
Funding supports large-animal studies and clinical-grade manufacturing of novel systems designed to overcome oxygenation and fibrosis barriers in cell therapy Ithaca, NY—September 23, 2025 — Persista Bio®, Inc. today announced it has been awarded two competitive grants from the U.S. National Institutes of Health (NIH) to accelerate development of its O2Line™ Oxygenated Cell Therapy Platform. The awards, […]